In IBD, the precursor to TransPath‐C, or TransComp‐R, which uses the same principles, identified elevated ITGA1 expression as a driver of anti‐TNF therapy resistance in patients: a molecular feature discernible in the mouse data that was predictive of patient phenotype. Here, ITGA1 is linked to inflammatory bowel disease.